Servicio de Información Comunitario sobre Investigación y Desarrollo - CORDIS

Adjuventicity of immunostimulating complexes

Initially cell mediated, antibody and cytokine responses are being investigated in laboratory animals following immunization with chemically defined immunostimulating complexes (ISCOM) carrying the Epstein-Barr virus (EBV) envelope glycoprotein gp340. Gp340-ISCOMs of varying but defined triterpenoid composition are being made in order to determine the contribution made by the individual components in inducing a given type of immune response. The EBV glycoprotein gp340 has already been shown to be a protective immunogen in a primate model of lymphoma induced by EBV. In this model it is clear that immune protection is mainly provided by cell mediated immune responses. Methods of assessing the type of cell mediated immune responses in the tamarin are being developed from those already used with mice and humans.

Large scale production of pure gp340 has been achieved in milligramme quantities on a routine basis. Progress has been made on the construction of chemically defined ISCOMS such that batches have been made containing various levels of the immunologically active triterpenoids and have been used to immunize mice and tamarins. Cytokine, cell mediated and antibody responses to gp340-ISCOMS are presently being evaluated.

Reported by

UNIVERSITY OF BRISTOL
University Walk
BS8 1TD BRISTOL, CLIFTON
United Kingdom
See on map
Síganos en: RSS Facebook Twitter YouTube Gestionado por la Oficina de Publicaciones de la UE Arriba